Compound News and Research

RSS

Calistoga Pharmaceuticals commences CAL-101 trial in combination with Rituxan and/or Treanda

Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced the initiation of a Phase 1 trial of CAL-101, the Company's oral, PI3K delta inhibitor, in combination with standard of care agents Rituxan® (rituximab) and/or Treanda® (bendamustine) in patients with relapsed or refractory indolent non-Hodgkin's lymphoma or chronic lymphocytic leukemia.

7 Apr 2010

Brazil healthcare market to reach $129.9 billion in 2012

On the road to global economic recovery, the BRIC countries (Brazil, Russia, India and China) are setting up a new scene. Brazil, in particular, is the 9th economy in the world and is expected to reach the 8th position by 2012. New opportunities set a promising healthcare market perspective with a strong potential for further growth.

7 Apr 2010

Health Robotics introduces Virtual High-Availability Architecture for CytoCare and i.v.STATION robots

As part of its I.V. Room of the Future initiative to cooperate with other industry leaders, Health Robotics today announced the immediate availability of its revolutionary Virtual High-Availability Architecture (up to 99.99%), including state-of-the-art, virtualization compliant, cluster and fail-over, disaster recovery, and back-up solutions for its CytoCare and i.v.STATION robots [with future expansion to TPNstation when available], and its i.v.SOFT Workflow Engine for manual compounding.

7 Apr 2010

RXi Pharmaceuticals, TransDerm collaborate on study of RXi's proprietary compounds in dermatology applications

RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), and TransDerm, Inc., a biopharmaceutical company developing nucleic acid skin delivery technologies and therapeutics for skin disorders, announced today that they will collaborate on studying the potential utility of RXi's proprietary compounds in dermatology models.

7 Apr 2010

FDA grants "Fast Track" designation for Genta’s advanced gastric cancer drug tesetaxel

Genta Incorporated today announced that the U.S. Food and Drug Administration (FDA) has granted the Company's request for "Fast Track" designation of tesetaxel for treatment of patients with advanced gastric cancer. Tesetaxel -- a late Phase 2 oncology product -- is the leading oral taxane currently in clinical development.

7 Apr 2010

Investment report on Keryx Biopharmaceuticals from BeaconEquity.com

BeaconEquity.com announces an investment report featuring Keryx Biopharmaceuticals Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

6 Apr 2010

StockPreacher.com releases investment report on Repros Therapeutics

StockPreacher.com announces an investment report featuring Repros Therapeutics Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

6 Apr 2010

SAFC announces opening of $30M expansion to Madison Manufacturing facility in Verona, Wisconsin

SAFC®, a member of the Sigma-Aldrich® Group, today announced the opening of a $30 million expansion to its Madison Manufacturing facility in Verona, Wisconsin.

6 Apr 2010

Rush University Medical Center seeks LEED certification for new buildings

Rush University Medical Center is taking the lead in adopting environmentally friendly and sustainable design, construction and operation practices that not only promote the health of the environment, but also the health of patients and staff.

6 Apr 2010

Qutenza 8% patch now available for pain associated with PHN: NeurogesX

NeurogesX, Inc. announced today that Qutenza® (capsaicin) 8% patch, the first and only product containing prescription-strength capsaicin, is now available. Clinical studies have shown that a single one-hour Qutenza application can provide three months relief from pain associated with postherpetic neuralgia, the nerve pain that can occur after shingles.

6 Apr 2010

Dalfampridine drug for multiple sclerosis now available in the U.S.

A drug whose clinical benefit in treating multiple sclerosis was discovered at Rush University Medical Center was approved by the Food and Drug Administration on January 22 and is now available in the U.S.

6 Apr 2010

China's SFDA finds certain batches of Jiangsu Yanshen's human use rabies vaccine substandard

Simcere Pharmaceutical Group, a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today reported that China's State Food and Drug Administration ("SFDA") issued a statement on its investigation into the human use rabies vaccine manufactured by Jiangsu Yanshen Biological Technology Stock Co., Ltd.. Simcere obtained a controlling stake in Jiangsu Yanshen on October 24, 2009.

5 Apr 2010

SE5-OH with Natural S-equol supplement appears to be safe for pre- and post-menopausal women

Healthy pre-and post-menopausal Japanese women who took a supplement of SE5-OH containing Natural S-equol, a novel soy germ-based ingredient under development for the management of menopausal symptoms, had measures of reproductive hormones that stayed within normal limits throughout the study.

3 Apr 2010

U.S. Court upholds validity of Eli Lilly's Gemzar compound patent

Eli Lilly and Company today announced that the U.S. District Court for the Southern District of Indiana has upheld the validity of the company's compound patent on Gemzar® (gemcitabine HCl for injection). This decision maintains Lilly's U.S. exclusivity for Gemzar through November 15, 2010.

2 Apr 2010

Gold nanoparticles for detecting melamine in milk

University of Miami assistant professor in the College of Engineering, Na Li and her collaborators have developed a fast, economical and easy method to detect melamine in milk. Melamine is the compound found in contaminated pet food and in tainted dairy products from China in 2007 and 2008 respectively.

2 Apr 2010

Teva Pharmaceutical Industries' Gemzar patent litigation: U.S. court issues decision

Teva Pharmaceutical Industries Ltd. announced today that the U.S. District Court for the Southern District of Indiana issued a decision yesterday on two patents for Gemzar® (gemcitabine); the compound patent expiring on November 15, 2010, and a method of use patent expiring on May 7, 2013.

2 Apr 2010

ChromaDex signs agreement for commercial development of pterostilbene from University of Mississippi and USDA

A natural products chemistry company has licensed the rights for a promising botanical compound from the University of Mississippi and the Agricultural Research Service, which is the principal intramural scientific research agency of the U.S. Department of Agriculture.

2 Apr 2010

Innovative drug design wins medical research prize

The development of a new way to treat iron overload disease has won the 2010 Sir Zelman Cowen Universities Fund Prize for Medical Research.

1 Apr 2010

Catalyst Pharmaceutical Partners reports net loss of $7.24M for fourth-quarter 2009

Catalyst Pharmaceutical Partners, Inc., a biopharmaceutical company that acquires, in-licenses, develops and commercializes prescription drugs for the treatment of diseases of the central nervous system, today reported financial results for the fourth quarter and year ended December 31, 2009.

1 Apr 2010

BELLUS Health initiates Phase I clinical study for NRM8499

BELLUS Health Inc. announced today that, on March 30, 2010, the Company initiated a Phase I clinical study for NRM8499, a prodrug of tramiprosate. NRM8499 is intended for the treatment of Alzheimer's disease.

1 Apr 2010

Compound News and Research

Calistoga Pharmaceuticals commences CAL-101 trial in combination with Rituxan and/or Treanda

Brazil healthcare market to reach $129.9 billion in 2012

Health Robotics introduces Virtual High-Availability Architecture for CytoCare and i.v.STATION robots

RXi Pharmaceuticals, TransDerm collaborate on study of RXi's proprietary compounds in dermatology applications

FDA grants "Fast Track" designation for Genta’s advanced gastric cancer drug tesetaxel

Investment report on Keryx Biopharmaceuticals from BeaconEquity.com

StockPreacher.com releases investment report on Repros Therapeutics

SAFC announces opening of $30M expansion to Madison Manufacturing facility in Verona, Wisconsin

Rush University Medical Center seeks LEED certification for new buildings

Qutenza 8% patch now available for pain associated with PHN: NeurogesX

Dalfampridine drug for multiple sclerosis now available in the U.S.

China's SFDA finds certain batches of Jiangsu Yanshen's human use rabies vaccine substandard

SE5-OH with Natural S-equol supplement appears to be safe for pre- and post-menopausal women

U.S. Court upholds validity of Eli Lilly's Gemzar compound patent

Gold nanoparticles for detecting melamine in milk

Teva Pharmaceutical Industries' Gemzar patent litigation: U.S. court issues decision

ChromaDex signs agreement for commercial development of pterostilbene from University of Mississippi and USDA

Innovative drug design wins medical research prize

Catalyst Pharmaceutical Partners reports net loss of $7.24M for fourth-quarter 2009

BELLUS Health initiates Phase I clinical study for NRM8499

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News